One case study presented a 49-year-old female with metastatic pancreatic cancer (harbouring BRAF and P53 mutations) responding to gemcitabine followed by dabrafenib and trametinib (a MEK inhibitor) treatment [120]. This evidence concerns the gene BRAF and familial pancreatic carcinoma.